Biogen is set to invest USD 2 billion in a major new manufacturing facility in North Carolina, USA, reinforcing its commitment to domestic pharmaceutical production amid increasing pressure from the U.S. government to reduce dependency on imported drugs. The investment was announced as President Donald Trump continues to push for localised manufacturing and potential tariffs on pharmaceutical imports.

The upcoming site will serve as a hub for biologics production, supporting Biogen’s pipeline of therapies for neurological and rare diseases. This strategic move not only enhances the company’s operational resilience but also strengthens its presence in the USA, one of its key markets.

Biogen stated that the facility will employ advanced manufacturing technologies and is expected to create significant employment opportunities in the region. The site will also bolster the company’s supply chain capabilities, ensuring quicker turnaround times and reducing vulnerability to global disruptions—lessons learned during the COVID-19 pandemic.

The announcement aligns with a broader industry trend, where several major pharmaceutical companies, including AstraZeneca, Roche, and Eli Lilly, have pledged billions in U.S.-based manufacturing to adapt to shifting trade and regulatory dynamics. Trump’s administration has emphasised reducing reliance on foreign pharmaceutical ingredients and finished products, calling it a matter of national security.

Biogen’s decision comes as part of a proactive strategy to remain ahead of potential policy shifts and maintain competitiveness in the global drug manufacturing landscape. The North Carolina site is poised to become a critical part of Biogen’s long-term growth and innovation strategy.